{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '6.10.', 'Treatment Compliance', 'The Investigator should promote treatment compliance by stating that compliance is', \"necessary for the patient's safety and the validity of the trial. The prescribed dose, timing,\", 'and mode of administration may not be changed. All dates and start and end time of IMP', 'administration and any deviations from the intended regimen must be recorded.', '6.11.', 'Handling Missed Doses of the Investigational Medicinal Product', 'Patients will receive 4 weekly IV infusions of IMP at a dose of 10 mg/kg over a period of', '1 hour during each Treatment Cycle.', 'All efforts will be done to ensure that the patient receives the 4 administrations of IMP within', 'the allowed time windows. However, if a patient misses 1 or more doses in any Treatment', 'Cycle, the patient will not be discontinued early from the trial or from further randomized', 'treatment and will complete all further visits and assessments according to the general SoA', '(Table 1). This patient may be eligible for further Treatment Cycles during the trial.', 'In case a dose needs to be delayed for more than 3days, the dosing should be skipped to', 'ensure two consecutive doses are given with an interval of at least 3 days.', '6.12.', 'Accountability of Investigational Medicinal Product', 'Detailed instructions on accountability of the IMP will be included in the IMP management', 'manual (pharmacy manual).', '6.13.', 'Storage of Blood Samples in the Trial', 'Any remaining samples after the analysis per protocol has been completed may be stored for', 'up to 15 years for future additional research to address any scientific questions related to', 'ARGX-113 or MG, unless this would not be allowed according to local regulations or the', 'patient would not agree.', '7.', 'TRIAL ASSESSMENTS', '7.1.', 'Efficacy and Quality of Life', 'Efficacy assessments will be assessed using MG-ADL, QMG, and MGC, and quality of life', 'will be measured using MG-QoL15r and EQ-5D-5L. All these assessments have to be', 'performed pre-dose on all IMP infusion days and following the order specified in the general', 'SoA (Table 1), and prior to any other assessment at each visit except for the assessment of', 'weight (if applicable) and signing of the ICF at the Screening visit.', 'The MG-ADL, QMG, and MGC assessments for a given patient are preferentially assessed', 'by one and the same trained evaluator throughout the course of the trial whenever possible.', 'argenx BVBA', 'Confidential', 'Page 75 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'For patients who are unable to read and write, the patient questionnaires MG-QoL15r and', 'EQ-5D-5L can be completed by a caregiver. In that case, the caregiver should read out loud', 'the questions (without given any personal interpretation or explanation to the patient) and', 'complete the exact answer as given by the patient.', '7.1.1.', 'Myasthenia Gravis-Activities of Daily Living', 'The MG-ADL is an 8-item patient-reported scale (Appendix 1) to assess MG symptoms and', 'their effects on daily activities. It evaluates the capacity to perform different activities of', 'daily living such as talking, chewing, swallowing, breathing, brushing the teeth/combing the', 'hair, or arising from the chair and it also assesses double vision and eyelid droop. It is a', 'discrete quantitative variable in which the 8 items are rated from 0 to 3 and the total score', 'can point from 0 to 24, with higher total scores indicating more impairment. The assessments', 'to be performed using MG-ADL (Appendix 1) do not require any equipment to assess MG', 'symptoms and their effects on daily activities. The scoring of MG-ADL should be performed', 'by a trained and certified evaluator.', '7.1.2.', 'Quantitative Myasthenia Gravis', 'The QMG quantifies disease severity based on impairments of body functions and structures', 'as defined by the International Classification of Functioning, Disability and Health', '(WHO 2001).', 'The QMG consists of 13 items (Appendix 2) that assess ocular, bulbar, and limb function.', 'Out of the 13 items, 6 are timed tests of endurance measured in seconds. Each item has a', 'possible score from 0-3. The total possible score is 39, where higher total scores indicate', 'more severe impairments. It is based on quantitative testing of specific muscle groups to', 'assess limb function. It requires minimal equipment such as spirometer, mouthpieces that fit', 'the spirometer, nose clips, stopwatch, cups and water for swallowing tests, goniometer,', \"dynamometer, and is based on the trained rater's examination. The scoring of QMG should\", 'be performed by a trained evaluator.', '7.1.3.', 'Myasthenia Gravis Composite', \"The MGC has 10 items (Appendix 3) combining a trained rater's examination and patient\", 'reported outcomes. The 2 ocular items are derived from QMG. It has 3 items on muscle', 'strength (deltoids, hip flexors, and neck flexors or extensors) and 4 items on bulbar function', '(swallowing, chewing, breathing, and speech functions), based on the clinical history. Each', 'item is scored on an ordinal scale with 4 possible categories, but the items are weighted,', 'whereby bulbar impairments weigh more than ocular ones. The impairments that need to be', 'examined by the Investigator include ptosis or upward gaze, double vision, eye closure, neck', 'flexion, shoulder abduction, and hip flexion. The patient reported outcomes under MGC are', 'talking, chewing, swallowing, and breathing. The maximum total possible score is 50, with', 'argenx BVBA', 'Confidential', 'Page 76 of 110']\n\n###\n\n", "completion": "END"}